Premium
MapLight Therapeutics Inc (MPLT)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | Dr. Christopher A. KroegerFounder, President, CEO & Director | -118,24k | 3,21M | Automatic Disposition | 27,19 - 28,15 | 114,12k | -50,89% |
| 2026-05-07 | Dr. James Woodruff LillieChief Scientific Officer | -721,00 | 20,39k | Automatic Disposition | 28,28 | 242,73k | -0,30% |
| 2026-05-07 | Dr. Erin Pennock FoffChief Medical Officer | -4,44k | 126,64k | Automatic Disposition | 28,52 - 29,10 | 346,06k | -1,27% |
| 2026-05-07 | Dr. Christopher A. KroegerFounder, President, CEO & Director | -68,49k | 1,95M | Automatic Disposition | 27,48 - 30,56 | 1,61M | -4,07% |
| 2026-05-11 | Mr. Kristopher L. HansonGeneral Counsel & Secretary | -13,92k | 419,26k | Automatic Disposition | 27,61 - 30,56 | 162,33k | -7,90% |
| 2026-05-04 | Mr. Kristopher L. HansonGeneral Counsel & Secretary | -13,92k | 388,18k | Automatic Disposition | 27,50 - 30,08 | 13,87k | -50,09% |
| 2026-05-04 | Dr. Christopher A. KroegerFounder, President, CEO & Director | -49,74k | 1,41M | Automatic Disposition | 27,50 - 30,08 | 300,85k | -14,19% |
| 2026-05-04 | Dr. James Woodruff LillieChief Scientific Officer | -51,71k | 1,47M | Automatic Disposition | 27,50 - 30,08 | 49,34k | -51,17% |
| 2026-05-04 | Mr. Vishwas SetiaInitié | -36,37k | 1,02M | Automatic Disposition | 27,36 - 30,12 | 356,26k | -9,26% |
| 2026-05-04 | Dr. Erin Pennock FoffChief Medical Officer | -50,28k | 1,43M | Automatic Disposition | 27,50 - 30,08 | 350,50k | -12,55% |
| 2026-04-27 | Mr. Jonathan GillisChief Admin & Acc Officer, Principal Accounting Officer and Interim CFO, Principal Financial Officer | -69,84k | 2,09M | Automatic Disposition | 28,94 - 30,83 | 0,00 | -100,00% |
| 2026-04-27 | Dr. Anatol KreitzerChief Discovery Officer | -45,42k | 1,35M | Automatic Disposition | 28,96 - 30,50 | 211,19k | -17,70% |
| 2026-04-15 | Dr. Anatol KreitzerChief Discovery Officer | -3,32k | 88,24k | Vente | 26,61 | 66,08k | -4,78% |
| 2026-04-15 | Dr. James Woodruff LillieChief Scientific Officer | -4,51k | 122,57k | Vente | 26,82 - 27,49 | 101,05k | -4,28% |
| 2026-04-15 | Dr. Erin Pennock FoffChief Medical Officer | -3,21k | 86,86k | Vente | 26,84 - 27,49 | 400,78k | -0,80% |
| 2026-04-15 | Mr. Jonathan GillisChief Admin & Acc Officer, Principal Accounting Officer and Interim CFO, Principal Financial Officer | -3,59k | 95,53k | Vente | 26,61 | 69,30k | -4,93% |
| 2026-04-15 | Mr. Kristopher L. HansonGeneral Counsel & Secretary | -1,83k | 49,13k | Vente | 26,80 - 27,49 | 27,79k | -6,17% |
| 2026-04-15 | Mr. Vishwas SetiaInitié | -2,92k | 78,57k | Vente | 26,87 - 27,49 | 36,44k | -7,42% |
| 2026-04-15 | Dr. Robert C. MalenkaCo-Founder & Member of Scientific Advisory Board | -8,59k | 231,15k | Automatic Disposition | 26,90 | 149,40k | -5,44% |
| 2026-04-15 | Dr. Christopher A. KroegerFounder, President, CEO & Director | -19,19k | 521,15k | Vente | 26,93 - 27,49 | 350,59k | -5,19% |
| 2026-02-20 | Dr. Robert C. MalenkaCo-Founder & Member of Scientific Advisory Board | -14,20k | 260,40k | Vente | 18,03 - 19,06 | 141,54k | -9,11% |
| 2026-02-18 | Mr. George A. PavlovIndependent Chairman of the Board | 25,00k | 441,17k | Achat | 17,48 - 17,86 | 25,00k | - |
| 2026-02-13 | Dr. Robert C. MalenkaCo-Founder & Member of Scientific Advisory Board | -12,12k | 220,63k | Vente | 18,21 | 155,74k | -7,22% |
| 2026-02-10 | Dr. Robert C. MalenkaCo-Founder & Member of Scientific Advisory Board | -6,86k | 124,33k | Vente | 18,00 - 18,12 | 167,86k | -3,93% |
| 2026-02-10 | Dr. Timothy J. GarnettIndependent Director | 14,12k | 252,68k | Achat | 17,89 | 40,55k | 53,45% |
| 2026-02-02 | Dr. Robert C. MalenkaCo-Founder & Member of Scientific Advisory Board | -7,04k | 126,86k | Vente | 18,00 - 18,02 | 174,72k | -3,87% |
| 2026-01-28 | Dr. Robert C. MalenkaCo-Founder & Member of Scientific Advisory Board | -34,40k | 635,86k | Vente | 18,11 - 19,05 | 181,76k | -15,91% |
| 2026-01-27 | Dr. Anatol KreitzerChief Discovery Officer | -42,10k | 756,94k | Sale to Issuer | 17,98 | 52,28k | -44,61% |
| 2026-01-27 | Mr. Vishwas SetiaInitié | -33,38k | 600,21k | Sale to Issuer | 17,98 | 31,28k | -51,63% |
| 2026-01-27 | Dr. James Woodruff LillieChief Scientific Officer | -45,06k | 810,09k | Sale to Issuer | 17,98 | 94,40k | -32,31% |
| 2026-01-27 | Mr. Kristopher L. HansonGeneral Counsel & Secretary | -26,01k | 467,61k | Sale to Issuer | 17,98 | 23,90k | -52,11% |
| 2026-01-27 | Dr. Christopher A. KroegerFounder, President, CEO & Director | -204,15k | 3,67M | Sale to Issuer | 17,98 | 301,95k | -40,34% |
| 2026-01-27 | Mr. Jonathan GillisChief Admin & Acc Officer, Principal Accounting Officer and Interim CFO, Principal Financial Officer | -22,05k | 396,46k | Sale to Issuer | 17,98 | 65,79k | -25,10% |
| 2026-01-27 | Dr. Erin Pennock FoffChief Medical Officer | -44,62k | 802,20k | Sale to Issuer | 17,98 | 390,48k | -10,25% |
| 2025-10-28 | Novo Holdings A/SSociété | 2,73M | 0,00 | Derivative Exercise and Retained Stock | - | - | - |
| 2025-10-28 | Novo Holdings A/SSociété | 952,94k | 16,20M | Achat | 17,00 | - | - |
| 2025-10-28 | Catalyst4, IncSociété | 14,26M | 0,00 | Derivative Exercise and Retained Stock | - | 19,70M | 262,01% |
| 2025-10-28 | Catalyst4, IncSociété | 5,44M | 92,50M | Achat | 17,00 | 19,70M | 38,17% |
| 2025-10-28 | Dr. Christopher A. KroegerFounder, President, CEO & Director | 3,90k | 0,00 | Derivative Exercise and Retained Stock | - | 285,44k | 1,38% |
| 2025-10-28 | Dr. Robert C. MalenkaCo-Founder & Member of Scientific Advisory Board | 3,90k | 0,00 | Derivative Exercise and Retained Stock | - | 31,67k | 14,02% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
